The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein
Authors:
- 1 May 2011
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 408 (2) , 344-349
Abstract
No abstract availableKeywords
Funding Information
- Seventh Framework Programme
- Wellcome Trust
- Leukaemia and Lymphoma Research
This publication has 24 references indexed in Scilit:
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1Blood, 2010
- ABC transporters in cancer: more than just drug efflux pumpsNature Reviews Cancer, 2010
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 ProteinsJournal of Medicinal Chemistry, 2008
- Bcl-2 inhibitors: small molecules with a big impact on cancer therapyCell Death & Differentiation, 2008
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorCancer Research, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitorExpert Review of Anticancer Therapy, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- An inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature, 2005
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999